Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01793649 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01793649 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 7 participants.
The verdict
NCT01793649, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.
Interventions
- DRUG GS-5737
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01793649
The ClinicalTrials.gov registry entry for NCT01793649 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GS-5737 is the first listed.
NCT01793649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01793649 about?
NCT01793649 is a clinical study titled "A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects". This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.
What is the current status of trial NCT01793649?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2012-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01793649?
The interventions under investigation include: GS-5737 (DRUG).
Who is sponsoring clinical trial NCT01793649?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.